Evidence map›Paper›PMID 40208257›Full record

ArticleAnnals of the American Thoracic Society2025

Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States.

Yiming Luo, Shervin Assassi, Maureen D Mayes, Tracy M Frech, Virginia D Steen, Carrie Richardson, Lorinda Chung, Nora Sandorfi, John M VanBuren, Monica Harding and 20 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of the American Thoracic Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Yiming LuoColumbia University Irving Medical Center New York, New York.ORCID 0000-0001-7710-2425
Shervin AssassiUniversity of Texas Health Science Center at Houston Houston, Texas.
Maureen D MayesUniversity of Texas Health Science Center at Houston Houston, Texas.
Tracy M FrechVanderbilt University Medical Center Nashville, Tennessee.
Virginia D SteenGeorgetown University Medical Center Washington, District of Columbia.
Carrie RichardsonNorthwestern University Chicago, Illinois.
Lorinda ChungStanford University and Palo Alto VA Health Care System Palo Alto, California.
Nora SandorfiUniversity of Pennsylvania Philadelphia, Pennsylvania.
John M VanBurenUniversity of Utah Salt Lake City, Utah.
Monica HardingUniversity of Utah Salt Lake City, Utah.
Jessica S AlveyUniversity of Utah Salt Lake City, Utah.
Brian SkaugUniversity of Texas Health Science Center at Houston Houston, Texas.
Zsuzsanna H McMahanUniversity of Texas Health Science Center at Houston Houston, Texas.
Kimberly S LakinHospital for Special Surgery New York City, New York.
Carleigh ZahnUniversity of Michigan Ann Arbor, Michigan.
Sonali J BrackenDuke University Durham, North Carolina.
Dorota J Lebiedz-OdrobinaUniversity of Utah Salt Lake City, Utah.
Jerry A MolitorUniversity of Minnesota Minneapolis, Minnesota.
Luke B EvninScleroderma Research Foundation San Francisco, California.
Duncan F MooreNorthwestern University Chicago, Illinois.
Ankoor ShahDuke University Durham, North Carolina.
Flavia V CastelinoMassachusetts General Hospital Boston, Massachusetts.
Elizabeth R VolkmannUniversity of California, Los Angeles Los Angeles, California.ORCID 0000-0003-3750-6569
Faye N HantMedical University of South Carolina Charleston, South Carolina.
Ashima MakolMayo Clinic Rochester, Minnesota.
Ami A ShahJohns Hopkins University Baltimore, Maryland.
Laura K HummersJohns Hopkins University Baltimore, Maryland.
Jessica K GordonHospital for Special Surgery New York City, New York.
Dinesh KhannaUniversity of Michigan Ann Arbor, Michigan.
Elana J BernsteinColumbia University Irving Medical Center New York, New York.ORCID 0000-0001-5560-6390

Funding

CTSA UM1 Program at University of UtahUM1TR004409 · NCATS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI RACHEL HESS, Jennifer Juhl Majersik · 2023 to 2026
$21.9M
Vasculopathy and Systemic Sclerosis-Associated Interstitial Lung DiseaseR01HL164758 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Elana J. Bernstein · 2022 to 2026
$3.5M
Pathogenic effects of the DNASE1L3 R206C variant in systemic sclerosisK08AR081402 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Brian Skaug · 2022 to 2026
$821k
Screening Chest CT to Detect Interstitial Lung Disease in Systemic SclerosisK23AR075112 · NIAMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BERNSTEIN, ELANA · 2019 to 2023
$794k
B Cell-Fibroblast Crosstalk Promotes Chronic GVHD of the LungK38AI185078 · NIAID · DUKE UNIVERSITY · PI BRACKEN, SONALI JAGDISH · 2024 to 2025
$208k
National Institute of Allergy and Infectious Diseases K38-AI-185078NCATS NIH HHS UM1 TR004409NHLBI NIH HHS R01 HL164758NHLBI NIH HHS R01-HL-164758NIAID NIH HHS K38 AI185078NIAMS NIH HHS K08 AR081402NIAMS NIH HHS K23 AR075112NIAMS NIH HHS K23-AR-075112NIAMS NIH HHS K24-AR-080217Rheumatology Research Foundation Scientist Development AwardScleroderma Research FoundationU.S. Department of Defense W81XWH2210163
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40208257
PMCPMC12329330

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.